The question remains of whether Ly6C+ monocytes that still infiltrate into GBM in CCR2-deficient tumor-bearing mice express CCR2 and whether a subset exists that does not express CCR2, thereby negating any positive survival benefit in tumor-bearing mice. This evidence concerns the gene CCR2 and glioblastoma.